SCHEMBL4586640

SCHEMBL4586640

CC(=O)C(=O)N(C)CC(=O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.38
EYA2 O00167 1/20 0.38
APP P05067 1/20 0.38
ACE P12821 1/20 0.38
MVD P53602 1/20 0.36
LMNA P02545 2/20 0.36
TSHR P16473 2/20 0.36
BLM P54132 2/20 0.36
PMP22 Q01453 2/20 0.36
KDM4E B2RXH2 1/20 0.36
CHRM2 P08172 1/20 0.36
ADRA2A P08913 1/20 0.36
ALOX15 P16050 1/20 0.36
DRD1 P21728 1/20 0.36
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
CYP2C19 P33261 1/20 0.36
ADRA1A P35348 1/20 0.36
DRD3 P35462 1/20 0.36
SLC6A3 Q01959 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14409182 0.80 TDP1 (0.35) TDP1EYA2APPACEMVD
SCHEMBL1597034 0.78
SCHEMBL9214812 0.77 TDP1 (0.36) TDP1EYA2APPACEMVD
SCHEMBL321404 0.76 TDP1 (0.39) TDP1EYA2APPACELMNA
Methyl Alcohol SCHEMBL3155059 0.76 CHRM1 (0.41) TDP1EYA2APPACEMVD
SCHEMBL11293864 0.75 TDP1 (0.35) TDP1EYA2APPACEMVD
SCHEMBL112280 0.75
SCHEMBL9216352 0.74
SCHEMBL22540356 0.74
SCHEMBL12521172 0.73 EGLN1 (0.40) TDP1EYA2APPACEMVD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6221836-B1 Composition of pyruvate and anabolic protein and method for increasing fat loss in a mammal PAXTON KING BEALE 2001-04-24 US claimed
US-6008252-A Method for increasing muscle mass in a mammal BEALE PAXTON K (US) 1999-12-28 US claimed
US-5919767-A ADJUST PROTEIN CONCNETRATION IN MUSCLES PAX BEALE AND SOPHIE TAGGART TRUST DATED AUGUST 26, 1997, THE 1999-07-06 US claimed
EP-0914109-A1 COMPOSITION OF PYRUVATE AND PROTEIN AND METHOD FOR INCREASING PROTEIN CONCENTRATION IN A MAMMAL Beale, Paxton K. (US) 1999-05-12 EP claimed
EP-0914108-A1 COMPOSITION OF PYRUVATE AND ANTI-CORTISOL COMPOUNDS AND METHOD FOR INCREASING PROTEIN CONCENTRATION IN A MAMMAL Beale, Paxton K. (US) 1999-05-12 EP claimed
US-5756469-A SYNERGISTIC COMPOSITION FOR ENTERIC ADMINISTRATION PAX BEALE AND SOPHIE TAGGART TRUST DATED AUGUST 26, 1997, THE 1998-05-26 US claimed
US-5716926-A ENHANCING THE PHYSICAL ENDURANCE OF MAMMAL BY ADMINISTERING TO MAMMAL THE ANABOLIC PROTEIN AND PYRUVATE Beale, Paxton K. (US) 1998-02-10 US claimed
WO-1998004254-A1 COMPOSITION OF PYRUVATE AND PROTEIN AND METHOD FOR INCREASING PROTEIN CONCENTRATION IN A MAMMAL BEALE PAXTON K (US) 1998-02-05 WO claimed
WO-1998004253-A1 COMPOSITION OF PYRUVATE AND ANTI-CORTISOL COMPOUNDS AND METHOD FOR INCREASING PROTEIN CONCENTRATION IN A MAMMAL BEALE PAXTON K (US) 1998-02-05 WO claimed
US-20080293702-A1 Nitric Oxide Enhancing Pyruvate Compounds, Compositions and Methods of Use NITROMED, INC. (US) 2008-11-27 US disclosed
US-20080287407-A1 Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use NITROMED, INC. (US) 2008-11-20 US disclosed
EP-1692107-A4 NITRIC OXIDE RELEASING PYRUVATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE NITROMED INC (US) 2008-10-29 EP disclosed
EP-1971340-A2 NITRIC OXIDE ENHANCING PYRUVATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE Nitromed, Inc. (US) 2008-09-24 EP disclosed
WO-2007117180-A1 AZAHETEROCYCLES, COMBINATORY LIBRARY, FOCUSED LIBRARY, PHARMACEUTICAL COMPOSITION AND METHODS FOR THE PRODUCTION THEREOF 'CHEMICAL DIVERSITY RESEARCH INSTITUTE' LTD. (RU) 2007-10-18 WO disclosed
US-5472980-A Reducing insulin resistance in mammals with amino acid derivatives ABBOTT LABORATORIES (US) 1995-12-05 US disclosed
EP-0636117-A1 USE OF PYRUVAMIDE AND SELECTED PYRUVYL-AMINO ACIDS ABBOTT LABORATORIES (US) 1995-02-01 EP disclosed
US-5312985-A Reaction of sodium pyruvate with thionyl chloride and oxalyl chloride to form pyruvyl chloride, then reaction with 1,1,1,3,3,3-hexamethyldisilazane and methanol to form pyruvamide ABBOTT LABORATORIES (US) 1994-05-17 US disclosed
US-5283260-A Oral ingesting a pyruvyl-amino acid compound before a glucose tolerance test ABBOTT LABORATORIES (US) 1994-02-01 US disclosed
WO-1993021147-A1 METHOD OF ADMINISTERING PYRUVATE AND METHODS OF SYNTHESIZING PYRUVATE PRECURSORS ABBOTT LABORATORIES (US) 1993-10-28 WO disclosed
US-5256697-A Covalently linked pyruvyl-amino compound ABBOTT LABORATORIES 1993-10-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293702-A1 Nitric Oxide Enhancing Pyruvate Compounds, Compositions and Methods of Use PC, PDK1, NOS3 TDP1 2486/4885EYA2 1134/4885APP 1377/4885
US-20080287407-A1 Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use PC, PDK1, NOS3 TDP1 501/4885EYA2 1919/4885APP 2378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.